RPG Life Sciences surges 15% to hit a 52-week high after Q1 net profit jumps 102% QoQ

In its Q1 results released on July 19, the company informed the stock exchanges that its net profit increased 21% YoY to ₹26.76 crore in Q1FY25 compared to ₹22.1 crore in Q1FY24. Sequentially, the company’s net profit for the June quarter surged over 102% QoQ from ₹13.24 crore in Q4FY24.

RPG Life Sciences’ revenue from operations for the June quarter of FY25 grew nearly 12% year-on-year to ₹165.42 crore compared to ₹147.78 crore in the June quarter of FY24. The company’s revenue from operations grew 30% from ₹126.99 crore in Q4FY24.

Commenting on the results, Yugal Sikri, managing director of RPG Life Sciences Ltd, said that the company is looking to modernise its Active Pharmaceutical Ingredient (API) and Formulation plants and research and development laboratories. The company is also looking forward to developing a ‘smart product pipeline’.

“While we are on course to modernise both our API and Formulations plants - by infusion of significant capex, our modernised R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth and the API business is also showing promising growth,” Sikri said.

RPG Life Sciences Ltd, a part of RPG Enterprises, is a leading integrated pharmaceutical player. The company operates in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. RPG Life Sciences Ltd produces a wide range of quality, affordable medicines.

RPG Life Sciences shares closed 1.98% higher at ₹1,830 apiece on the NSE. The stock has gained 95.56% in the last one year. In the past six months, the stock has rallied 23.03% and 24.18% in a month.